ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer

NCT00555919 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Lonaprisan (ZK 230211, BAY86-5044)
DRUG: Lonaprisan (ZK 230211, BAY86-5044)

Sponsor

Bayer